Literature DB >> 22644660

The antidiabetic effect of mesenchymal stem cells is unrelated to their transdifferentiation potential but to their capability to restore Th1/Th2 balance and to modify the pancreatic microenvironment.

Fernando Ezquer1, Marcelo Ezquer, David Contador, Micaela Ricca, Valeska Simon, Paulette Conget.   

Abstract

Type 1 diabetes mellitus (T1DM) is a chronic metabolic disease that results from cell-mediated autoimmune destruction of insulin-producing cells. In T1DM animal models, it has been shown that the systemic administration of multipotent mesenchymal stromal cells, also referred as to mesenchymal stem cells (MSCs), results in the regeneration of pancreatic islets. Mechanisms underlying this effect are still poorly understood. Our aims were to assess whether donor MSCs (a) differentiate into pancreatic β-cells and (b) modify systemic and pancreatic pathophysiologic markers of T1DM. After the intravenous administration of 5 × 10(5) syngeneic MSCs, we observed that mice with T1DM reverted their hyperglycemia and presented no donor-derived insulin-producing cells. In contrast, 7 and 65 days post-transplantation, MSCs were engrafted into secondary lymphoid organs. This correlated with a systemic and local reduction in the abundance of autoaggressive T cells together with an increase in regulatory T cells. Additionally, in the pancreas of mice with T1DM treated with MSCs, we observed a cytokine profile shift from proinflammatory to antinflammatory. MSC transplantation did not reduce pancreatic cell apoptosis but recovered local expression and increased the circulating levels of epidermal growth factor, a pancreatic trophic factor. Therefore, the antidiabetic effect of MSCs intravenously administered is unrelated to their transdifferentiation potential but to their capability to restore the balance between Th1 and Th2 immunological responses along with the modification of the pancreatic microenvironment. Our data should be taken into account when designing clinical trials aimed to evaluate MSC transplantation in patients with T1DM since the presence of endogenous precursors seems to be critical in order to restore glycemic control.
Copyright © 2012 AlphaMed Press.

Entities:  

Mesh:

Year:  2012        PMID: 22644660     DOI: 10.1002/stem.1132

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  62 in total

Review 1.  Mesenchymal stromal cells to halt the progression of type 1 diabetes?

Authors:  Per-Ola Carlsson; Olle Korsgren; Katarina Le Blanc
Journal:  Curr Diab Rep       Date:  2015-07       Impact factor: 4.810

2.  Direct comparison of the abilities of bone marrow mesenchymal versus hematopoietic stem cells to reverse hyperglycemia in diabetic NOD.SCID mice.

Authors:  Edith J Arany; Muhammad Waseem; Brenda J Strutt; Astrid Chamson-Reig; Adam Bernardo; Elizabeth Eng; David J Hill
Journal:  Islets       Date:  2018-08-15       Impact factor: 2.694

Review 3.  Multipotent mesenchymal stromal cells: A promising strategy to manage alcoholic liver disease.

Authors:  Fernando Ezquer; Flavia Bruna; Sebastián Calligaris; Paulette Conget; Marcelo Ezquer
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 4.  Role of mesenchymal stem cells in cell life and their signaling.

Authors:  Shihori Tanabe
Journal:  World J Stem Cells       Date:  2014-01-26       Impact factor: 5.326

5.  Immunogenicity of allogeneic mesenchymal stem cells transplanted via different routes in diabetic rats.

Authors:  Le-Hui Gu; Tian-Tian Zhang; Yang Li; Hong-Jie Yan; Hui Qi; Fu-Rong Li
Journal:  Cell Mol Immunol       Date:  2014-09-22       Impact factor: 11.530

6.  Therapeutic effects of stem cell on hyperglycemia, hyperlipidemia, and oxidative stress in alloxan-treated rats.

Authors:  Walid Hamdy El-Tantawy; Ekram Nemr Abd Al Haleem
Journal:  Mol Cell Biochem       Date:  2014-03-07       Impact factor: 3.396

Review 7.  Advances in islet encapsulation technologies.

Authors:  Tejal Desai; Lonnie D Shea
Journal:  Nat Rev Drug Discov       Date:  2016-12-23       Impact factor: 84.694

8.  Conventional and Alternative Mesenchymal Stem Cell Therapies for the Treatment of Diabetes.

Authors:  Lubna Rifai; Fatima A Saleh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  Human urine-derived stem cells play a novel role in the treatment of STZ-induced diabetic mice.

Authors:  Tianxue Zhao; Deng Luo; Yun Sun; Xin Niu; Yang Wang; Chen Wang; Weiping Jia
Journal:  J Mol Histol       Date:  2018-04-19       Impact factor: 2.611

10.  Allogeneic Mesenchymal Stem Cell Therapy Promotes Osteoblastogenesis and Prevents Glucocorticoid-Induced Osteoporosis.

Authors:  Bingdong Sui; Chenghu Hu; Xinyi Zhang; Pan Zhao; Tao He; Cuihong Zhou; Xinyu Qiu; Nan Chen; Xinyi Zhao; Yan Jin
Journal:  Stem Cells Transl Med       Date:  2016-06-30       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.